Detection of cell-free ERCC1 and thymidylate synthase (TS) mRNA in malignant effusions and its association with anticancer drug sensitivity

Anticancer Research

Volumn 28, Issue 2 A, 2008, Pages 1085-1091

  Wang, Lifeng ^a   Liu, Baorui ^a   Wang, Tingting ^a   Ding, Yitao ^a   Qian, Xiaoping ^a   Zhao, Yang ^b  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Cell free mRNA; ERCC1; Malignant effusion; Real time quantitative PCR; Thymidylate synthase

Indexed keywords

CISPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROURACIL; MESSENGER RNA; THYMIDYLATE SYNTHASE;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; DRUG SENSITIVITY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MALE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; STATISTICAL SIGNIFICANCE; TUMOR CELL;

ADULT; AGED; AGED, 80 AND OVER; ASCITES; CELL-FREE SYSTEM; CISPLATIN; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; ENDONUCLEASES; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; PLEURAL EFFUSION, MALIGNANT; RNA, MESSENGER; THYMIDYLATE SYNTHASE;

EID: 42549123150     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Lee JH, Hong YS, Ryu JS and Chang JH: P53 and FHIT mutations and microsatellite alterations in malignancy-associated pleural effusion. Lung Cancer 44: 33-42, 2004.
2. Neragi-Miandoab S: Malignant pleural effusion. Current and evolving approaches for its diagnosis and management. Lung cancer 54: 1-9, 2006.
3. Ceppi P, Volante M, Novello S, Rapa I, Danenberg KD, Danenberg PV, Cambieri A, Selvaggi G, Saviozzi S, Calogero R, Papotti M and Scagliotti GV: ERCC1 and RRM1 gene expression but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncology 17(12): 1818-1825, 2006.
4. Rosell R, Cecere F, Santarpia M, Reguart N and Taron M: Predicting the outcome of chemotherapy for lung cancer. Curr Opin Pharmacol 6: 323-331, 2006.
5. Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, Stahel R, Sabatier L, Pignon JP, Tursz T, Le Chevalier T, Soria JC and IALT Bio Investigators: DNA repair by ERCC1 in non-small cell lung cancer and cisplatin-based adjuvant chemotherapy. N Eng J Med 335(10): 983-991, 2006.
6. Park DJ and Lenz HJ: Determination of chemosensitivity in gastric cancer. Curr Opin Pharmacol 6: 337-344, 2006.
7. Shirota Y, Stoehlmacher J, Brabender J, Xiong YP, Uetake H, Danenberg KD, Groshen S, Tsao-Wei DD, Danenberg PV and Lenz HJ: ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 19(23): 4298-4304, 2001.
8. Aschele C, Debernardis D, Tunesi G, Maley F and Sobrero A: Thymidylate synthase protein expression in primary colorectal cancer compared with the corresponding distant metastases and relationship with the clinical response to 5-fluorouracil. Clin Cancer Res 6: 4797-4802, 2000.
9. Paradiso A, Simone G, Petroni S, Leone B, Vallejo C, Lacava J, Romero A, Machiavelli M, De Lena M, Allegra CJ and Johnston PG: Thymidilate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients. Br J Cancer 82(3): 560-567, 2000.
10. Tong YK and Dennis Lo YM: Diagnostic developments involving cell-free (circulating) nucleic acids. Clin Chim Acta 363: 187-196, 2006.
11. Bremnes RM, Sirera R and Camps C: Circulating tumour-derived DNA and RNA markers in blood: a tool for early detection, diagnostics, and follow-up? Lung Cancer 49(1): 1-12, 2005.
12. Xu Y, Yao LH, Li HX, Ouyang T, Li J, Wang T, Fan Z, Lin B, Lu Y, Larsson O and Xie Y: Presence of erbB2 mRNA in the plasma of breast cancer patients is associated with circulating tumor cells and negative estrogen and progesterone receptor status. Breast Cancer Res Treat 97: 49-55, 2006.
13. Silva JM, Rodriguez R, Garcia JM, Muñoz C, Silva J, Dominguez G, Provencio M, España P and Bonilla F: Detection of epithelial tumor RNA in the plasma of colon cancer patients is associated with advanced stages and circulating tumour cells. Gut 50: 530-534, 2002.
14. Li Y, Elashoff D, Oh M, Sinha U, St John MA, Zhou X, Abemayor E and Wong DT: Serum circulating human mRNA profiling and its utility for oral cancer detection. J Clin Oncol 24(11): 1754-1760, 2006.
15. Miura N, Shiota G, Nakagawa T, Maeda Y, Sano A, Marumoto A, Kishimoto Y, Murawaki Y and Hasegawa J: Sensitive detection of human telomerase reverse transcriptase (hTERT) mRNA in the serum of patients with hepatocellular carcinoma. Oncology 64: 430-434, 2003.
16. H mutation status in patients with chronic lymphocytic leukaemia. Br J Haematol 133: 690-694, 2006.
17. Andreotti PE, Cree IA, Kurbacher CM, Hartmann DM, Linder D, Harel G, Gleiberman I, Caruso PA, Ricks SH and Untch M: Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma. Cancer Res 55: 5276-5282, 1995.
18. Mercer SJ, Somers SS, Knight LA, Whitehouse PA, Sharma S, Di Nicolantonio F, Glaysher S, Toh S and Cree IA: Portsmouth Upper GI Cancer Multi-Disciplinary Team: Heterogeneity of chemosensitivity of esophageal and gastric carcinoma. Anti-Cancer Drugs 14(6): 397-403, 2003.
19. Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25(4): 402-408, 2001.
20. Ugurel S, Schadendorf D, Pföhler C, Neuber K, Thoelke A, Ulrich J, Hauschild A, Spieth K, Kaatz M, Rittgen W, Delorme S, Tilgen W and Reinhold U: Dermatologic Cooperative Oncology Group: In vitro drug sensitivity predicts response and survival after individulized sensitivity-directed chemotherapy in metastatic melanoma: a multicenter phase II trial of the dermatologic cooperative oncology group. Clin Cancer Res 12(18): 5454-5463, 2006.
21. Konecny G, Crohns C, Pegram M, Felber M, Lude S, Kurbacher C, Cree IA, Hepp H and Untch M: Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer. Gynecol Oncol 77: 258-263, 2000.
22. Kurbacher CM, Cree IA, Bruckner HW, Brenne U, Kurbacher JA, Müller K, Ackermann T, Gilster TJ, Wilhelm LM, Engel H, Mallmann PK and Andreotti PE: Use of an ex vivo ATP luminescence assay to direct chemotherapy for recurrent ovarian cancer. Anticancer Drugs 9(1): 51-57, 1998.
23. Di Nicolantonio F, Mercer SJ, Knight LA, Gabriel FG, Whitehouse PA, Sharma S, Fernando A, Glaysher S, Di Palma S, Johnson P, Somers SS, Toh S, Higgins B, Lamont A, Gulliford T, Hurren J, Yiangou C and Cree IA: Cancer cell adaptation to chemotherapy. BMC Cancer 5: 78, 2005.
24. Fakhrejahani E, Miyamoto A and Tanigawa N: Correlation between thymidylate synthase and dihydropyrimidine dehydrogenase mRNA level and in vitro chemosensitivity to 5-fluorouracil, in relation to differentiation in gastric cancer. Cancer Chemother Pharmacol 60(3): 437-446, 2007.
25. Noda E, Maeda K, Inoue T, Nishihara T, Nishiguchi Y, Ohira M and Hirakawa K: Expression of genes for 5-FU-metabolizing enzymes and response to irinotecan plus 5-FU-leucovorin in colorectal cancer. Anticancer Res 26(6C): 4653-4658, 2006.
26. Bendardaf R, Lamlum H, Elzagheid A, Ristamäki R and Pyrhönen S: Thymidylate synthase expression levels: a prognostic and predictive role in advanced colorectal cancer. Oncol Rep 14(3): 657-662, 2005.
27. Kimura H, Fujiwara Y, Sone T, Kunitoh H, Tamura T, Kasahara K and Nishio K: High sensitivity detection of epidermal growth factor receptor mutations in the pleural effusion of non-small cell lung cancer patients. Cancer Sci 97(7): 642-648, 2006.
28. Kimura H, Fujiwara Y, Sone T, Kunitoh H, Tamura T, Kasahara K and Nishio K: EGFR mutation status in tumor-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib. Br J Cancer 95: 1390-1395, 2006.
29. Stevens EV, Raffeld M, Espina V, Kristensen GB, Trope' CG, Kohn EC and Davidson B: Expression of xeroderma pigmentosum A protein predicts improved outcome in metastatic ovarian carcinoma. Cancer 103(11): 2313-2319, 2005.
30. Farrugia DC, Ford HE, Cunningham D, Danenberg KD, Danenberg PV, Brabender J, McVicar AD, Aherne GW, Hardcastle A, McCarthy K and Jackman AL: Thymidylate synthase expression in advanced colorectal cancer predicts for response to raltitrexed. Clin Cancer Res 9: 792-801, 2003.
31. Saebo M, Skjelbred CF, Nexo BA, Wallin H, Hansteen IL, Vogel U and Kure EH: Increased mRNA expression levels of ERCC1, OGG1 and RAI in colorectal adenomas and carcinomas. BMC Cancer 6: 208, 2006.
32. Davidson B: Malignant effusions: from diagnosis to biology. Diagn Cytopathol 31(4): 246-254, 2004.
33. Kassis J, Klominek J and Kohn EC: Tumor microenviroment: what can effusions teach us? Diagn Cytopathol 33(5): 316-319, 2004.